Ligand approach to IGF

MedImmune MEDI-573 targets ligands in IGF pathway, where many cancer drugs fail

While drug companies have been targeting insulin-like growth factor-1 receptor since it was first implicated in cancer almost two decades ago, the strategy has yet to bear fruit because of tumor resistance and off-target effects. AstraZeneca plc's MedImmune LLC subsidiary thinks it can avoid those issues by targeting the receptor's ligands IGF-1 and IGF-2 with its MEDI-573 antibody.

Jerry McMahon, SVP of R&D and head of the oncology innovative medicines unit at MedImmune, said preclinical

Read the full 743 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE